Physician profile
Michelle S Dodder
NPI 1134115967
$1,655.67
in general payments reported to CMS, 2019-2025
24 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $136 · 2021: $156 · 2022: $237 · 2023: $475 · 2024: $179 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $269.50 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Aspira Women'S Health INC | $203.41 | 2023-2024 | Ova1 |
| Astellas Pharma US INC | $202.03 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $151.53 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Exeltis, USA INC. | $121.59 | 2021-2025 | Slynd |
| Optumhealth Care Solutions, LLC | $101.41 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Mayne Pharma Commercial LLC | $81.86 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $76.29 | 2020-2025 | Gardasil 9, Gardasil |
| Therapeuticsmd, INC. | $60.98 | 2019-2022 | |
| Millicent US INC | $60.46 | 2020-2025 | Femlyv |
| Organon LLC | $46.01 | 2021-2023 | Nexplanon |
| Masimo Corporation | $32.32 | 2019 | |
| Allergan, INC. | $30.61 | 2019-2020 | |
| Biogen, INC. | $29.52 | 2025 | Zurzuvae |
| Myovant Sciences INC. | $23.49 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $23.47 | 2023 | |
| Scynexis, INC. | $22.45 | 2022 | |
| Bsn Medical INC | $22.14 | 2025 | |
| Roche Diagnostics Corporation | $20.17 | 2020 | |
| Vertical Pharmaceuticals, LLC | $19.20 | 2019 | |
| Lupin INC. | $15.95 | 2019 | |
| Mission Pharmacal Company | $14.17 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.10 | 2023 | |
| Channel Medsystems, INC. | $13.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Dodder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.